China-NZ tripartite and catalyst seeding: a collaborative research workshop for professionals and researchers in health, biology and biomedical sciences

Date: Tuesday 29 Jan, 9am - 5pm
Location: AUT City Campus
WG Building, WG801-802
New Zealand
China-NZ tripartite and catalyst seeding: a collaborative research workshop for professionals and researchers in health, biology and biomedical sciences 01/29/2019 09:00 01/29/2019 17:00 Delivered by Auckland University of Technology, Fudan University, Shanghai Jiatong University and Xinjiang University, this workshop is funded by Education New AUT City Campus, WG Building, WG801-802, Auckland , New Zealand

Delivered by Auckland University of Technology, Fudan University, Shanghai Jiatong University and Xinjiang University, this workshop is funded by Education New Zealand’s China-NZ Tripartite Fund and Royal Society Catalyst Seeding Fund. Speakers from Shanghai Fudan University, Shanghai Jiaotong University, Xinjiang University and Auckland University of Technology will present their research results to New Zealand researchers, and hopefully to establish wider research collaboration.

Who should attend

This collaborative research is perfect for researchers, academics and professional practitioners in the fields of health, biology, and all biomedical sciences.

RSVP and more information

For more information about the workshop, or to RSVP, contact:

Jun Lu, PhD
Associate Professor of Biomedical Science and Pharmacology
Head of Research, School of Interprofessional Health Studies and School of Science
Faculty of Health & Environmental Sciences

Workshop schedule

8.30am - 9am: On Arrival Tea/Coffee

8.50am - 9am: Opening by Pro-Vice Chancellor and Dean of Health and Environmental Sciences, Professor Max Abbott, CNZM

9am - 9.45am: Professor Weili Yan, Topic: Periconceptional parental folate nutrition and congenital heart disease in offspring: a prospective cohort study.

9.45am - 10.30am: Professor Richard Siegert, Topic: New directions in research on depression

10.30am - 11am: Morning Tea (Break)

11am - 11.45am: Associate Professor Baohong Zhang, Topic: Biopharmaceutical Development on Bispecific Antibody and Engineered CHO cell line

11.45am - 12.30pm: Professor Tianlei Ying, Topic: Development of germline-like human monoclonal antibodies for the treatment of infectious diseases

12.30pm - 1.15pm: Lunch (Break)

1.15pm - 2pm: Dr. Yan Li, Topic: ABC Transporters and GI Cancer Resistance

2pm - 2.45pm: Associate Professor Dong-Xu Liu, Topic: The role of SHON in precision medicine for breast cancer treatment

2.45pm - 3.30pm: Professor Tianlei Ying, Topic: A platform for extending half-life of biotherapeutics

3.30pm - 4pm: Afternoon Tea (Break)

4pm - 4.45pm: Professor Jinyao Li (via video conference), Topic: The development of therapeutic dendritic cell-based vaccine against cervical cancer

4.45pm - 5.30pm: Associate Professor Jun Lu, Topic: Investigation of Different Molecular Weight Fucoidan Fractions Derived from New Zealand Undaria pinnatifida in combination with GroA therapy in prostate cancer cell lines

6pm: Day Finishes

6.30pm - 8pm: Dinner served (WG407)

Speakers and topics

Professor Tianlei Ying, PhD

Fudan University, China
Research interests: antibody engineering, CAR-T, infectious diseases

Dr Tianlei Ying graduated from Fudan University with a PhD in 2010. After postdoctoral training at the National Cancer Institute, NIH, he joined the School of Basic Medical Sciences, Fudan University in 2014 as Professor and Chief of the Antibody Engineering and Drug Discovery Laboratory. Dr Ying's research interests include antibody-based therapies for cancer, HIV and other infectious diseases. In the past 5 years, he has published over 50 papers in journals such as Nat Biotech, Nat Commun, Cell Host Microbe, J Infect Dis, mAbs, and co-authored 15 patents and patent applications. Currently, he is involved in the development of novel antibody fragments of small size and long half-lives; this technology could also be used for extending serum half-lives of protein therapeutics. He also developed several exceptionally large human antibody libraries, and identified panels of highly potent fully human mAbs against cancer and infectious diseases. Some of these mAbs have been licensed to top biopharmaceutical companies and are expected to move into the clinic shortly.

Professor Jinyao Li, PhD

Director of Xinjiang Key Laboratory of Biological Resources and Genetic Engineering
College of Life Science and Technology, Xinjiang University, Urumqi, China

Dr Jinyao Li has focused on the cancer immunotherapy, development of adjuvant and antitumor drugs. He has published over 80 papers in journals including J Immunol, Food Chemistry, Clinical Immunology, and Vaccine. Currently, he is involved in the development of a therapeutic dendritic cell-based vaccine against advanced cervical cancer. This vaccine has shown the clinical benefit in the inhibition of tumour growth and the improvement of the patient’s life quality.

Professor Weili Yan, PhD

Director of Department of Clinical Epidemiology & Clinical trial unit
Children’s Hospital of Fudan University, National Children Medical Centre, Shanghai

Professor Weili Yan is a genetic epidemiologist with expertise in obesity-related cardiovascular disease in children population.  Her research focuses on genetic epidemiology and epigenetic regulation of childhood obesity and related cardiovascular risk in children. In addition, she leads the department of clinical epidemiology of to provide methodology support to large clinical studies, such as national multicentre neonatal congenital heart disease screening projects, the first national autism spectrum disorder survey in children and the Shanghai pre-conceptional parent-child cohort (SPCC). She is the hospital manager of the clinical trial registry at

Associate Professor Baohong Zhang, PhD

Associate Dean, School of Pharmacy, Shanghai Jiao Tong University
Engineering Research Center of Cell & Therapeutic Antibody, MOE, China

Dr Baohong Zhang got her PhD degree from the Ocean University of China in 2002. Then She joined the School of Pharmacy, Shanghai Jiao Tong University. She is engaged in biopharmaceutical development. She has focused on the bispecific antibody, a bispecific antibody-drug conjugate, engineered CHO cell line by Crisp/Cas9 technology. Currently, she is also involved in the field of developing novel antibodies in collaboration with computer-aided design and expressing mAbs in a stem cell system.

Professor Richard Siegert, PhD

Psychology and Rehabilitation, Auckland University of Technology

Professor Richard Siegert has previously worked at Victoria University of Wellington, the University of Otago and King’s College London. His research interests include psychometrics, outcome measurement in mental health and rehabilitation, goal setting and mindfulness techniques for people with chronic health conditions. Richard is on the editorial committee of the journals Disability and Rehabilitation and Mindfulness. He is an author on over 130+ in international journals and author of two popular textbooks on rehabilitation. His most recent book is Rehabilitation Goal Setting: Theory, Practice and Evidence published recently by CRC Press/Taylor and Francis. Richard is or has been the lead investigator on grants funded by NIMH (UK), RSNZ (Catalyst, Marsden) and HRC.

Associate Professor Jun Lu, PhD

Biomedical Science and Pharmacology, Auckland University of Technology

Dr Jun Lu graduated with a BSc in Environmental Science from East China Normal University, MSc in Marine Biology and PhD in Cancer Pharmacology from the University of Auckland. His research interest includes food for health, natural compounds for biomedical use, diabetes risk identification, and biomedical treatment for cancer, heart failure and diabetic nephropathy. He has published 90 journal articles in top journals like Cancer Research, Clinical Cancer Research, Diabetologia, Molecular Pharmacology, Food Chemistry, Oncotarget, and Obesity Surgery. He is the PI of this Tripartite Fund from Education New Zealand.

Dr Yan Li, PhD

School of Science, Auckland University of Technology

Dr Yan Li completed his clinical medical training in China and his Master of Science (Pharmacology) at the University of Auckland, New Zealand. After completing his PhD training at the University of Otago in 2007, Dr Li worked as a research fellow for the Tokyo University of Science, Tohoku University (Japan) and the University of Auckland.  He joined the Auckland University of Technology as a Senior Lecturer in 2012. Dr Li’s major research interests are membrane transporters and anti-cancer drug resistance, drug metabolism and pharmacokinetics, nanomedicine, and phytochemicals. He has received research grants from such bodies as the NZ Cancer Society, the NZ Lottery Board, AMRF, NZ Heart Foundation and JSPS.